2-[6-(aminomethyl)-2-pyridinyl]-1H-isoindole-1,3(2H)-dione | 848678-66-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[6-(aminomethyl)-2-pyridinyl]-1H-isoindole-1,3(2H)-dione
• 英文别名: 2-[6-(aminomethyl)pyridin-2-yl]isoindole-1,3-dione
• CAS: 848678-66-0
• 化学式: C₁₄H₁₁N₃O₂
• 分子量: 253.26
• InChiKey: AKIVFWDOPRMDCY-UHFFFAOYSA-N

物化性质

• 沸点：
  482.8±55.0 °C(Predicted)
• 密度：
  1.407±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  76.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[6-(aminomethyl)-2-pyridinyl]-1H-isoindole-1,3(2H)-dione 、 甲乙酐 反应 2.0h， 生成 2-(imidazo[1,5-a]pyridin-5-yl)isoindoline-1,3-dione
  参考文献：
  名称：

  [EN] DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN
  [FR] UREES HETEROAROMATIQUES MODULANT LA FONCTION DU RECEPTEUR VANILLOIODE-1 (VR1)

  摘要：

  公开号：

  WO2005028445A3
• 作为产物：
  描述：

  N-(2-溴甲基吡啶-6-基)邻苯二甲酰亚胺 在 乌洛托品 、 盐酸 作用下， 以 二氯甲烷 、 乙醇 、 水 为溶剂， 生成 2-[6-(aminomethyl)-2-pyridinyl]-1H-isoindole-1,3(2H)-dione
  参考文献：
  名称：

  [EN] DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN
  [FR] UREES HETEROAROMATIQUES MODULANT LA FONCTION DU RECEPTEUR VANILLOIODE-1 (VR1)

  摘要：

  公开号：

  WO2005028445A3

文献信息

• FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF
  申请人：Beijing Innocare Pharma Tech Co., Ltd.

  公开号：US20190185472A1

  公开（公告）日：2019-06-20

  The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I′), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I′) is the same as defined in the specification.

  本发明涉及融合的杂环衍生物，其制备方法以及在医学上的应用。具体而言，本发明涉及一种由式(I′)表示的新型衍生物，或其药学上可接受的盐，含有该衍生物或其药学上可接受的盐的药物组合物，以及制备该衍生物及其药学上可接受的盐的方法。本发明还涉及利用该衍生物及其药学上可接受的盐，或含有该衍生物及其药学上可接受的盐的药物组合物，在制备药物中的应用，特别是作为IDO抑制剂药物，用于治疗和/或预防癌症。其中，式(I′)的每个取代基与规范中定义的相同。
• Vitronectin receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US20010034445A1

  公开（公告）日：2001-10-25

  Compounds of formula (I) are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis. 1

  式(I)的化合物被披露，它们是在治疗骨质疏松症中有用的维特龙蛋白受体拮抗剂。
• Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain
  申请人：Fletcher Robert Stephen

  公开号：US20070078156A1

  公开（公告）日：2007-04-05

  Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated; R 1 is halogen, hydroxy, C 1-6 alkyl, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, hydroxyC 1-6 alkoxy, C 3-7 cycloalkyl, C 3-5 cycloalkylC 1-4 alkyl, NR 7 R 8 , C 1-6 alkyl substituted with NR 7 R 8 , C, 1-6 alkoxy substituted with NR 7 R 8 , oxo, cyano, SO 2 NR 7 R 8 , CONR 7 R 8 , NHCOR 9 or NHSO 2 R 9 ; R 2 is halogen, hydroxy, C 1-6 alkyl, halo C 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, hydroxyC 1-6 alkoxy, C 3-7 cycloalkyl, C 3-5 cycloalkylC 1-4 alkyl, NR 7 R 8 , C 1-6 alkyl substituted with NR 7 R 8 , C 1-6 , alkoxy substituted with NR 7 R 8 , cyano, SON 2 R 7 R 8 , CONR 7 R 8 , NHCOR 9 , or NHSO 2 R 9 ; R 3 and R 4 are each independently hydrogen, C 1-6 , alkyl, phenyl or halophenyl; R 5 and R 6 are, at each occurrence, independently hydrogen, C 1-6 alkyl, phenyl, halophenyl or carboxy; X is an oxygen or sulfur atom; Y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; n is either zero or an integer from 1 to 3; p is either zero or an integer from, 1 to 4; and q is either zero or an integer from 1 to 3; the other substituents are defined in claim 1; are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).

  式(I)的化合物：其中A、B和D分别为C、N、O或S；E为C或N；五元环内的点圈表示该环可能不饱和或部分饱和；R1为卤素、羟基、C1-6烷基、卤代C1-6烷基、羟基C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、羟基C1-6烷氧基、C3-7环烷基、C3-5环烷基C1-4烷基、NR7R8、C1-6烷基取代的NR7R8、C1-6烷氧基取代的NR7R8、氧代、氰基、SO2NR7R8、CONR7R8、NHCOR9或NHSO2R9；R2为卤素、羟基、C1-6烷基、卤代C1-6烷基、羟基C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、羟基C1-6烷氧基、C3-7环烷基、C3-5环烷基C1-4烷基、NR7R8、C1-6烷基取代的NR7R8、C1-6烷氧基取代的NR7R8、氰基、SON2R7R8、CONR7R8、NHCOR9或NHSO2R9；R3和R4分别独立地为氢、C1-6烷基、苯基或卤代苯基；R5和R6在每次出现时独立地为氢、C1-6烷基、苯基、卤代苯基或羧基；X为氧或硫原子；Y为芳基、杂芳基、碳环基或融合碳环基基团；n为零或1至3的整数；p为零或1至4的整数；q为零或1至3的整数；其他取代基在权利要求中定义；在治疗疼痛和其他通过调节vanilloid-1受体（VR1）功能改善的疾病中特别有用的治疗化合物。
• FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
  申请人：Beijing InnoCare Pharma Tech Co., Ltd.

  公开号：EP3505517A1

  公开（公告）日：2019-07-03

  The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I'), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I') is the same as defined in the specification.

  本发明涉及融合杂环衍生物、其制备工艺及其在医药中的用途。具体而言，本发明涉及一种由式（I'）表示的新型衍生物或其药学上可接受的盐、一种含有该衍生物或其药学上可接受的盐的药物组合物，以及制备该衍生物及其药学上可接受的盐的方法。本发明还涉及该衍生物及其药学上可接受的盐，或含有该衍生物及其药学上可接受的盐的药物组合物在制备治疗和/或预防癌症的药物（尤其是 IDO 抑制剂药物）中的用途。其中，式（I'）的各取代基与说明书中定义的相同。
• Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof
  申请人：Beijing Innocare Pharma Tech Co., Ltd.

  公开号：US11046682B2

  公开（公告）日：2021-06-29

  The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I′), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I′) is the same as defined in the specification.

  本发明涉及融合杂环衍生物、其制备工艺及其在医药中的用途。具体地说，本发明涉及一种由式（Ⅰ′）表示的新型衍生物或其药学上可接受的盐、含有该衍生物或其药学上可接受的盐的药物组合物，以及制备该衍生物及其药学上可接受的盐的方法。本发明还涉及该衍生物及其药学上可接受的盐，或含有该衍生物及其药学上可接受的盐的药物组合物在制备治疗和/或预防癌症的药物（尤其是 IDO 抑制剂药物）中的用途。其中式(I′)的各取代基与说明书中所定义的相同。